A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection

Autor: Xi Yu, Ying Wang, Min Zhang, Lingzhan Meng, Zhenwen Liu, Haibin Su, Ming Shi, Lei Jin, Fu-Sheng Wang, Rounan Xu, Yan-ling Sun, Hongbo Wang
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Graft Rejection
Male
medicine.medical_specialty
medicine.medical_treatment
Cell
Pilot Projects
Liver transplantation
Human Clinical Articles
Mesenchymal Stem Cell Transplantation
Gastroenterology
Umbilical cord
T-Lymphocytes
Regulatory
Dinoprostone
03 medical and health sciences
0302 clinical medicine
Human Clinical Article
Transforming Growth Factor beta
Internal medicine
medicine
Humans
Clinical Trials
Prostaglandin E2
Aged
biology
business.industry
Mesenchymal stem cell
Histology
Mesenchymal Stem Cells
Cell Biology
General Medicine
Transforming growth factor beta
Middle Aged
Adult Stem Cells
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
biology.protein
Acute rejection
Th17 Cells
Female
Stem cell
business
Developmental Biology
medicine.drug
Zdroj: Stem Cells Translational Medicine
ISSN: 2157-6580
2157-6564
Popis: Acute allograft rejection remains common after liver transplantation despite modern immunosuppressive agents. In addition, the long-term side effects of these regimens, including opportunistic infections, are challenging. This study evaluated the safety and clinical feasibility of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy in liver transplant patients with acute graft rejection. Twenty-seven liver allograft recipients with acute rejection were randomly assigned into the UC-MSC infusion group or the control group. Thirteen patients received one infusion of UC-MSCs (1 × 106/kg body weight); one patient received multiple UC-MSC infusions; 13 patients were used as controls. All enrolled patients received conventional immunosuppressive agents with follow-up for 12 weeks after UC-MSC infusions. No side effects occurred in treated patients. Four weeks after UC-MSC infusions, alanine aminotransferase levels had decreased markedly and remained lower throughout the 12-week follow-up period. Importantly, allograft histology was improved after administration of UC-MSCs. The percentage of regulatory T cells (Tregs) and the Treg/T helper 17 (Th17) cell ratio were significantly increased 4 weeks after infusions; in contrast, the percentage of Th17 cells showed a decreasing trend. In controls, the percentages of Tregs and Th17 cells and the Treg/Th17 ratio were statistically unchanged from the baseline measurements. Transforming growth factor beta 1 and prostaglandin E2 were increased significantly after UC-MSC infusions; by contrast, there were no significant changes in controls. Our data suggest that UC-MSC infusion for acute graft rejection following liver transplantation is feasible and may mediate a therapeutic immunosuppressive effect.
Databáze: OpenAIRE
Externí odkaz: